These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 23935207)
1. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339 [TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J; Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Czito BG; Bendell JC; Willett CG; Morse MA; Blobe GC; Tyler DS; Thomas J; Ludwig KA; Mantyh CR; Ashton J; Yu D; Hurwitz HI Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):472-8. PubMed ID: 17498568 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805 [TBL] [Abstract][Full Text] [Related]
10. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. van Dijk TH; Tamas K; Beukema JC; Beets GL; Gelderblom AJ; de Jong KP; Nagtegaal ID; Rutten HJ; van de Velde CJ; Wiggers T; Hospers GA; Havenga K Ann Oncol; 2013 Jul; 24(7):1762-1769. PubMed ID: 23524865 [TBL] [Abstract][Full Text] [Related]
13. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042 [TBL] [Abstract][Full Text] [Related]
15. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M; Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Dipetrillo T; Pricolo V; Lagares-Garcia J; Vrees M; Klipfel A; Cataldo T; Sikov W; McNulty B; Shipley J; Anderson E; Khurshid H; Oconnor B; Oldenburg NB; Radie-Keane K; Husain S; Safran H Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):124-9. PubMed ID: 20947267 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Velenik V; Ocvirk J; Music M; Bracko M; Anderluh F; Oblak I; Edhemovic I; Brecelj E; Kropivnik M; Omejc M Radiat Oncol; 2011 Aug; 6():105. PubMed ID: 21880132 [TBL] [Abstract][Full Text] [Related]
18. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210 [TBL] [Abstract][Full Text] [Related]
19. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134 [TBL] [Abstract][Full Text] [Related]
20. Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Ricardi U; Racca P; Franco P; Munoz F; Fanchini L; Rondi N; Dongiovanni V; Gabriele P; Cassoni P; Ciuffreda L; Morino M; Filippi AR; Aglietta M; Bertetto O Med Oncol; 2013; 30(2):581. PubMed ID: 23606239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]